CONSTANTINE CANNON, LLP for AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform
Foreign entity interest: S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHEN S ANDERSON | — |
| W STEPHEN CANNON | — |
| DAVID D GOLDEN New | — |
Health Issues HCR
S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
Foreign entity interest: S. 319 -- drug reimportation H.R. 2 -- healthcare reform bill repeal PDUFA reauthorization; Life sciences research tax credit legislation Orphan drug issues H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHEN S ANDERSON | — |
| W STEPHEN CANNON | — |
| DAVID D GOLDEN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.